Select Publications
Journal articles
2024, 'Chemotherapy and radiotherapy for advanced pancreatic cancer', Cochrane Database of Systematic Reviews, 2024, http://dx.doi.org/10.1002/14651858.CD011044.pub3
,2024, 'Oncological outcomes post transoral robotic surgery (TORS) for HPV-associated oropharyngeal squamous cell carcinoma, a single-centre retrospective Australian study', Journal of Robotic Surgery, 18, http://dx.doi.org/10.1007/s11701-024-01910-0
,2024, 'Approach to the Patient: New Era Emerges for Craniopharyngioma Management', Journal of Clinical Endocrinology and Metabolism, 109, pp. 2986 - 2996, http://dx.doi.org/10.1210/clinem/dgae503
,2024, 'Size matters: Biomolecular compositions of small and large extracellular vesicles in the urine of glioblastoma patients', Journal of Extracellular Biology, 3, http://dx.doi.org/10.1002/jex2.70021
,2024, 'Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response', Science Advances, 10, http://dx.doi.org/10.1126/sciadv.adl1197
,2024, '‘The Reports of My Death Are Greatly Exaggerated’—Evaluating the Effect of Necrosis on MGMT Promoter Methylation Testing in High-Grade Glioma', Cancers, 16, http://dx.doi.org/10.3390/cancers16101906
,2024, 'Prognostic and predictive biomarkers in central nervous system tumours: the molecular state of play', Pathology, 56, pp. 158 - 169, http://dx.doi.org/10.1016/j.pathol.2023.11.003
,2024, 'Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: A systematic review and meta-analysis', Experimental Dermatology, 33, http://dx.doi.org/10.1111/exd.14978
,2023, 'Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer', Clinical Colorectal Cancer, 22, pp. 457 - 463, http://dx.doi.org/10.1016/j.clcc.2023.08.006
,2023, 'Acetazolamide versus placebo for cerebral oedema requiring dexamethasone in recurrent and/or progressive high-grade glioma: phase II randomised placebo-controlled double-blind study', BMJ Supportive and Palliative Care, 13, pp. 354 - 362, http://dx.doi.org/10.1136/spcare-2022-004119
,2023, 'Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis', Melanoma Research, 33, pp. 316 - 325, http://dx.doi.org/10.1097/CMR.0000000000000900
,2023, 'Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas', Current Neurology and Neuroscience Reports, 23, pp. 263 - 276, http://dx.doi.org/10.1007/s11910-023-01268-0
,2023, 'Clinical Trials in the Brain Tumour Population: Challenges and Strategies for the Future', Current Oncology Reports, 25, pp. 589 - 598, http://dx.doi.org/10.1007/s11912-023-01394-5
,2023, 'Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma', Translational Oncology, 31, http://dx.doi.org/10.1016/j.tranon.2023.101638
,2023, 'Immune checkpoint inhibitors for advanced pancreatic cancer', Cochrane Database of Systematic Reviews, 2023, http://dx.doi.org/10.1002/14651858.CD014523
,2023, 'Impact of travel distance on outcomes for clinical trial patients: the Kinghorn Cancer Centre experience', Internal Medicine Journal, 53, pp. 242 - 249, http://dx.doi.org/10.1111/imj.15561
,2023, 'Association of chemotherapy dose intensity and age with outcomes in patients with Ewing's family sarcoma', Asia-Pacific Journal of Clinical Oncology, http://dx.doi.org/10.1111/ajco.13998
,2023, 'BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience', Frontiers in Oncology, 13, http://dx.doi.org/10.3389/fonc.2023.1154246
,2022, 'Determining the Research Priorities for Adult Primary Brain Tumours in Australia and New Zealand: A Delphi Study with Consumers, Health Professionals, and Researchers', Current Oncology, 29, pp. 9928 - 9955, http://dx.doi.org/10.3390/curroncol29120781
,2022, 'CSIG-13. CLINICAL IMPACT OF CDKN2A/B DELETIONS IN IDH-MUTANT ASTROCYTOMAS', Neuro-Oncology, 24, pp. vii41 - vii41, http://dx.doi.org/10.1093/neuonc/noac209.162
,2022, 'CTNI-42. GENOME-WIDE DNA METHYLATION PATTERNS IN VERTU: A RANDOMIZED PHASE II TRIAL OF VELIPARIB, RADIOTHERAPY AND TEMOZOLOMIDE IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA', Neuro-Oncology, 24, pp. vii81 - vii81, http://dx.doi.org/10.1093/neuonc/noac209.307
,2022, 'Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer', British Journal of Cancer, 127, pp. 1473 - 1478, http://dx.doi.org/10.1038/s41416-022-01903-6
,2022, 'Multi-Arm GlioblastoMa Australasia (MAGMA): Protocol for a multiarm randomised clinical trial for people affected by glioblastoma', BMJ Open, 12, http://dx.doi.org/10.1136/bmjopen-2021-058107
,2022, 'Barriers and potential solutions to international collaboration in neuro-oncology clinical trials: Challenges from the Australian perspective', Asia-Pacific Journal of Clinical Oncology, 18, pp. 259 - 266, http://dx.doi.org/10.1111/ajco.13606
,2022, 'Interobserver and intraobserver variability of RECIST assessment in ovarian cancer', International Journal of Gynecological Cancer, 32, pp. 656 - 661, http://dx.doi.org/10.1136/ijgc-2021-003319
,2022, 'PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities', Cancers, 14, http://dx.doi.org/10.3390/cancers14041003
,2022, 'Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma', Canadian Urological Association Journal, 16, http://dx.doi.org/10.5489/CUAJ.7467
,2022, 'What matters for people with brain cancer? Selecting clinical quality indicators for an Australian Brain Cancer Registry', Neuro-Oncology Practice, 9, pp. 68 - 78, http://dx.doi.org/10.1093/nop/npab055
,2021, 'LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study', BMJ Open, 11, http://dx.doi.org/10.1136/bmjopen-2021-054075
,2021, 'Outcomes from the use of computerized neurocognitive testing in a recurrent glioblastoma clinical trial', Journal of Clinical Neuroscience, 94, pp. 321 - 327, http://dx.doi.org/10.1016/j.jocn.2021.10.022
,2021, 'INNV-08. LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY', Neuro-Oncology, 23, pp. vi106 - vi107, http://dx.doi.org/10.1093/neuonc/noab196.420
,2021, 'RTID-05. THE MULTI-ARM GLIOBLASTOMA AUSTRALASIA (MAGMA) TRIAL', Neuro-Oncology, 23, pp. vi193 - vi194, http://dx.doi.org/10.1093/neuonc/noab196.767
,2021, 'Management of glioblastoma: An Australian perspective', Chinese Clinical Oncology, 10, http://dx.doi.org/10.21037/cco.2020.02.05
,2021, 'Altered presentation of oropharyngeal cancer, a 6-year review', ANZ Journal of Surgery, 91, pp. 1240 - 1245, http://dx.doi.org/10.1111/ans.16537
,2021, 'Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)', Journal of Clinical Oncology, 39, pp. 1108 - 1118, http://dx.doi.org/10.1200/JCO.20.02232
,2021, 'Development of a radiomic signature for predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer', Canadian Urological Association Journal, 16, http://dx.doi.org/10.5489/CUAJ.7294
,2021, 'Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer', Oncology (Switzerland), 99, pp. 49 - 56, http://dx.doi.org/10.1159/000510446
,2020, 'Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy', Frontiers in Endocrinology, 11, pp. 576027, http://dx.doi.org/10.3389/fendo.2020.576027
,2020, 'QOLP-23. PHASE II RANDOMISED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF ACETAZOLAMIDE VERSUS PLACEBO FOR CEREBRAL OEDEMA IN RECURRENT AND/OR PROGRESSIVE HIGH-GRADE GLIOMA REQUIRING TREATMENT WITH DEXAMETHASONE', Neuro-Oncology, 22, pp. ii179 - ii180, http://dx.doi.org/10.1093/neuonc/noaa215.748
,2020, 'Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium', European urology oncology, 3, pp. 530 - 539, http://dx.doi.org/10.1016/j.euo.2020.01.001
,2020, 'Deep sequencing of small RNAs from neurosurgical extracellular vesicles substantiates miR-486-3p as a circulating biomarker that distinguishes glioblastoma from lower-grade astrocytoma patients', International Journal of Molecular Sciences, 21, pp. 1 - 22, http://dx.doi.org/10.3390/ijms21144954
,2020, 'A comprehensive proteomic SWATH-MS workflow for profiling blood extracellular vesicles: A new avenue for glioma tumour surveillance', International Journal of Molecular Sciences, 21, pp. 1 - 26, http://dx.doi.org/10.3390/ijms21134754
,2020, 'Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database', Cancer Medicine, 9, pp. 4918 - 4928, http://dx.doi.org/10.1002/cam4.3228
,2020, 'Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab', Cancer Medicine, 9, pp. 4640 - 4647, http://dx.doi.org/10.1002/cam4.3116
,2020, 'Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma', Cancer Medicine, 9, pp. 3023 - 3032, http://dx.doi.org/10.1002/cam4.2948
,2020, 'Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastric and esophageal cancers', Journal of Gastrointestinal Oncology, 11, pp. 356 - 365, http://dx.doi.org/10.21037/jgo.2020.03.03
,2020, 'Exploring the role of novel medical therapies for aggressive pituitary tumors: A review of the literature—“are we there yet?”', Cancers, 12, pp. 308, http://dx.doi.org/10.3390/cancers12020308
,2020, 'Patterns of disease, treatment, and outcomes of esophageal cancer arising within a previous radiation treatment field.', Journal of Clinical Oncology, 38, pp. 328 - 328, http://dx.doi.org/10.1200/jco.2020.38.4_suppl.328
,2020, 'Preoperative serum artemin (ARTN) as a predictive biomarker of recurrence following curative resection for hepatocellular carcinoma (HCC).', Journal of Clinical Oncology, 38, pp. 571 - 571, http://dx.doi.org/10.1200/jco.2020.38.4_suppl.571
,2020, 'Randomized Phase III Study of FOLFOX Alone and with Pegilodecakin as Second-line Therapy in Patients with Metastatic Pancreatic Cancer (SEQUOIA).', Journal of Clinical Oncology, 38, pp. 637 - 637, http://dx.doi.org/10.1200/jco.2020.38.4_suppl.637
,